22nd May 2013 11:43
22 May 2013
LSE: VER
Vernalis Results of Annual General Meeting
Resolutions
Vernalis plc (LSE: VER) announces that all resolutions proposed to shareholders at its Annual General Meeting held today were duly passed.
All resolutions were approved on a show of hands. The number of proxy votes received for each resolution is set out below.
Resolution | For (including discretionary votes)* | Against* | Withheld | ||
Ordinary Resolutions (requires 50% majority) | |||||
1. That the audited accounts and related reports of the Directors and auditors for the year ended 31 December 2012 be received | 382,880,590 | (99.99 %) | 1,787 | (0.01 %) | 382 |
2. That the remuneration report contained within the report and accounts for the year ended 31 December 2012 be approved | 380,527,356 | (99.39 %) | 2,351,904 | (0.61 %) | 3,499 |
3. That Mr D Mackney be re-elected as a director | 382,872,771 | (99.99 %) | 8,757 | (0.01 %) | 1,231 |
4. That PricewaterhouseCoopers LLP be reappointed auditors and the Directors be authorised to determine their remuneration | 382,856,960 | (99.99 %) | 22,227 | (0.01 %) | 3,572 |
5. That the Directors be authorised to allot shares | 382,867,774 | (99.99 %) | 12,709 | (0.01 %) | 2,276 |
Special Resolutions (requires 75% majority) | |||||
6. That the Directors be authorised to disapply pre-emption rights | 382,855,841 | (99.99 %) | 20,249 | (0.01 %) | 6,669 |
7. That General Meetings, other than Annual General Meetings, may be called on not less than 14 clear days' notice | 382,871,943 | (99.99 %) | 8,691 | (0.01 %) | 2,125 |
*NB: A vote withheld is not a vote in law and, is not counted in the calculation of the votes for or against a resolution. Therefore, the percentage of votes cast excludes withheld votes
On 22 May 2013, there were 442,112,768 Vernalis plc ordinary shares in issue.
The full text of each resolution passed at the Annual General Meeting held earlier today, Wednesday 22 May 2013, is set out in the Notice of Annual General Meeting which is available for viewing on the Company's website at www.vernalis.com.
- ends -
Enquiries:
Vernalis | +44 (0) 118 938 0015 |
Ian Garland, Chief Executive Officer David Mackney, Chief Financial Officer
| |
Nomura Code Securities Limited | +44 (0) 20 7776 1200 |
Jonathan Senior, Juliet Thompson
| |
Brunswick Group | +44 (0) 20 7404 5959 |
Jon Coles
|
About Vernalis
Vernalis is a revenue generating development stage pharmaceutical company with significant expertise in drug development. The Group has one marketed product, frovatriptan for the acute treatment of migraine, an exclusive licensing agreement to develop and commercialise multiple novel products focussed on the US prescription cough cold market as well as seven programmes in its NCE development pipeline. Vernalis also has significant expertise in fragment and structure based drug discovery which it leverages to enter into collaborations with larger pharmaceutical companies. The Company's technologies, capabilities and products have been endorsed over the last five years by collaborations with leading pharmaceutical companies, including Biogen Idec, Endo, GSK, Genentech, Lundbeck, Menarini, Novartis, Servier and Tris.
For further information about Vernalis, please visit www.vernalis.com
Related Shares:
Vernalis PLC